The Bridge Program is convened and administered by Queensland University of Technology and involves a consortium of 10 pharmaceutical companies, universities and industry associations. The Bridge Program aims to boost the commercial outputs of Australian pharmaceutical research by improving the quality and quantity of commercial deals that arise from Australia’s pharmaceutical research sector.
Launched in June 2017, the program selects 100 participants annually from across Australia to take part in face-to-face and online training in the scientific, legal, financial, clinical, regulatory and reimbursement disciplines that contribute to research translation and the commercialisation of medicines. Program participants also benefit from direct exposure to networking opportunities with top pharmaceutical companies operating globally.
As part of the MTPConnect Project Fund Program, The Bridge Program was awarded industry matched funding to deliver an exciting education program that provides the necessary training to enable successful commercialisation of Australian pharmaceutical research. A key barrier identified in MTPConnect’s draft Sector Competitiveness Plan, and addressed by the Bridge Program, is the lack of commercialisation skills and business acumen across researchers and life science entrepreneurs. The Bridge Program is unique in its integration into venture capital and global pharmaceutical networks and its ability to share specific, detailed and practical know-how that will assist researchers and entrepreneurs to improve the quality and quantity of leads that they could offer for development, and to accelerate the process of commercialisation.